These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 27539027)

  • 1. Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation.
    Earley CJ; Uhl GR; Clemens S; Ferré S
    Sleep Med; 2017 Mar; 31():71-77. PubMed ID: 27539027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment with dopamine D3 receptor agonists induces a behavioral switch that can be rescued by blocking the dopamine D1 receptor.
    Dinkins ML; Lallemand P; Clemens S
    Sleep Med; 2017 Dec; 40():47-52. PubMed ID: 29221778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pathophysiology of restless legs syndrome].
    Miyamoto M; Miyamoto T; Iwanami M; Suzuki K; Hirata K
    Brain Nerve; 2009 May; 61(5):523-32. PubMed ID: 19514512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The heterotetrameric structure of the adenosine A
    Cortés A; Casadó-Anguera V; Moreno E; Casadó V
    Adv Pharmacol; 2019; 84():37-78. PubMed ID: 31229177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective.
    Clemens S; Rye D; Hochman S
    Neurology; 2006 Jul; 67(1):125-30. PubMed ID: 16832090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. D3 and D1 receptors: The Yin and Yang in the treatment of restless legs syndrome with dopaminergics.
    Clemens S; Ghorayeb I
    Adv Pharmacol; 2019; 84():79-100. PubMed ID: 31229178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the causes of augmentation in restless legs syndrome.
    Zeng P; Wang T; Zhang L; Guo F
    Front Neurol; 2023; 14():1160112. PubMed ID: 37840917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute.
    García-Borreguero D; Allen RP; Kohnen R; Högl B; Trenkwalder C; Oertel W; Hening WA; Paulus W; Rye D; Walters A; Winkelmann J; Earley CJ;
    Sleep Med; 2007 Aug; 8(5):520-30. PubMed ID: 17544323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding.
    Cervenka S; Pålhagen SE; Comley RA; Panagiotidis G; Cselényi Z; Matthews JC; Lai RY; Halldin C; Farde L
    Brain; 2006 Aug; 129(Pt 8):2017-28. PubMed ID: 16816393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine and the spinal cord in restless legs syndrome: does spinal cord physiology reveal a basis for augmentation?
    Paulus W; Schomburg ED
    Sleep Med Rev; 2006 Jun; 10(3):185-96. PubMed ID: 16762808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome.
    Paulus W; Trenkwalder C
    Lancet Neurol; 2006 Oct; 5(10):878-86. PubMed ID: 16987735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Restless legs: recent advances in basic research and therapy].
    Sieb JP
    Med Monatsschr Pharm; 2010 Apr; 33(4):133-9. PubMed ID: 20429403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenosine receptors as markers of brain iron deficiency: Implications for Restless Legs Syndrome.
    Quiroz C; Gulyani S; Ruiqian W; Bonaventura J; Cutler R; Pearson V; Allen RP; Earley CJ; Mattson MP; Ferré S
    Neuropharmacology; 2016 Dec; 111():160-168. PubMed ID: 27600688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopaminergic augmentation of restless legs syndrome.
    García-Borreguero D; Williams AM
    Sleep Med Rev; 2010 Oct; 14(5):339-46. PubMed ID: 20219397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation.
    Garcia-Borreguero D; Silber MH; Winkelman JW; Högl B; Bainbridge J; Buchfuhrer M; Hadjigeorgiou G; Inoue Y; Manconi M; Oertel W; Ondo W; Winkelmann J; Allen RP
    Sleep Med; 2016 May; 21():1-11. PubMed ID: 27448465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restless legs syndrome: pathophysiology and modern management.
    Nagandla K; De S
    Postgrad Med J; 2013 Jul; 89(1053):402-10. PubMed ID: 23524988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease).
    Earley CJ; Connor J; Garcia-Borreguero D; Jenner P; Winkelman J; Zee PC; Allen R
    Sleep Med; 2014 Nov; 15(11):1288-301. PubMed ID: 25201131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible sites of therapeutic action in restless legs syndrome: focus on dopamine and α2δ ligands.
    Thorpe AJ; Clair A; Hochman S; Clemens S
    Eur Neurol; 2011; 66(1):18-29. PubMed ID: 21709418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pivotal Role of Adenosine Neurotransmission in Restless Legs Syndrome.
    Ferré S; Quiroz C; Guitart X; Rea W; Seyedian A; Moreno E; Casadó-Anguera V; Díaz-Ríos M; Casadó V; Clemens S; Allen RP; Earley CJ; García-Borreguero D
    Front Neurosci; 2017; 11():722. PubMed ID: 29358902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmentation of restless leg syndrome (Willis-Ekbom disease) during long-term dopaminergic treatment.
    Garcia-Borreguero D; Benitez A; Kohnen R; Allen R
    Postgrad Med; 2015; 127(7):716-25. PubMed ID: 26077324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.